Elisabeth Rouits

Relevance of Different UGT1A1 Polymorphisms in Irinotecan-Induced Toxicity

Elisabeth Rouits, M. Boisdron‐Celle, Agnès Dumont et al. · Clinical Cancer Research · 2004 · 273 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study

Xu-Shan Sun, Yungan Tao, Christophe Le Tourneau et al. · The Lancet Oncology · 2020 · 130 citations

Medicine, Oncology, Radiation Oncology +11

Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study

Herbert I. Hurwitz, David C. Smith, Henry C. Pitot et al. · Cancer Chemotherapy and Pharmacology · 2015 · 77 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients

Elisabeth Rouits, Virginie Charasson, Aurélie Pétain et al. · British Journal of Cancer · 2008 · 56 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Brivaracetam Single and Multiple Rising Oral Dose Study in Healthy Japanese Participants: Influence of CYP2C19 Genotype

Armel Stockis, Shikiko Watanabe, Elisabeth Rouits et al. · Drug Metabolism and Pharmacokinetics · 2014 · 55 citations

Medicine, Pharmacokinetics, Pharmacology +11